The flow of money to startups trying to leverage CRISPR/Cas-9 technology for clinical purposes apparently is limitless. 

Intellia Therapeutics this week said that it raised $70 million in a Series B funding round that drew some heavyweight investors, including OrbiMed HealthCare Fund Management, Fidelity Management and Research, Janus Capital Management, and others. Founding investors Atlas Venture and Novartis also participated in the round. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.